Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GDRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGDRXGoodRx$6.66-0.4%$6.89$4.14▼$9.37$2.63B1.421.54 million shs404,235 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGDRXGoodRx-0.45%+1.68%+1.22%-0.45%+15.63%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGDRXGoodRx3.5122 of 5 stars4.20.00.00.02.61.71.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGDRXGoodRx2.47Hold$8.7831.80% UpsideCurrent Analyst RatingsLatest GDRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024GDRXGoodRxKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Weight ➝ Overweight$9.003/25/2024GDRXGoodRxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$7.50 ➝ $10.003/1/2024GDRXGoodRxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $7.503/1/2024GDRXGoodRxUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$5.00 ➝ $8.003/1/2024GDRXGoodRxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$7.00 ➝ $8.003/1/2024GDRXGoodRxThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.50 ➝ $7.503/1/2024GDRXGoodRxTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$12.00 ➝ $14.003/1/2024GDRXGoodRxTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$7.50 ➝ $8.003/1/2024GDRXGoodRxBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$8.00 ➝ $9.003/1/2024GDRXGoodRxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$7.00 ➝ $10.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGDRXGoodRx$750.27M3.51$0.41 per share16.21$1.93 per share3.45Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGDRXGoodRx-$8.87M-$0.02N/A21.483.67-1.18%2.45%1.25%5/9/2024 (Confirmed)Latest GDRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/AGDRXGoodRx$0.0870N/A-$0.0870N/AN/AN/A 2/29/2024Q4 2023GDRXGoodRx$0.02$0.02N/A$0.10$195.59 million$196.64 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGDRXGoodRxN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGDRXGoodRx0.857.127.12OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGDRXGoodRx63.77%Insider OwnershipCompanyInsider OwnershipGDRXGoodRx1.37%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGDRXGoodRx694395.00 million389.59 millionOptionableGDRX HeadlinesSourceHeadlineGDRX INVESTOR ALERT: Kessler Topaz Meltzer & Check, LLP Files A Securities Fraud Class Action Lawsuit Against GoodRX Holdings, Inc. And Encourages Investors With Losses To Contact The Firmbusinesswire.com - April 22 at 5:04 PMWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?marketbeat.com - April 22 at 6:05 AMWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (GDRX)marketbeat.com - April 22 at 6:05 AMIs GoodRx (GDRX) Outperforming Other Medical Stocks This Year?zacks.com - April 19 at 10:46 AMGoodRx (NASDAQ:GDRX) Stock Price Up 3.2%marketbeat.com - April 16 at 3:23 PMGoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of "Hold" from Analystsamericanbankingnews.com - April 16 at 2:36 AMMixed Inflation Readings Highlight Rocky Weeknasdaq.com - April 13 at 8:48 PMGoodRx Announces Date for First Quarter 2024 Earnings Release and Conference Callbusinesswire.com - April 11 at 4:09 PMGoodRx (NASDAQ:GDRX) Trading 2.1% Higher marketbeat.com - April 10 at 2:51 PMR1 RCM, Health Catalyst downgraded as KeyBanc reviews health-tech spacemsn.com - April 10 at 1:34 PMGoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earningsmarkets.businessinsider.com - April 10 at 1:34 PMGoodRx Stock Upgraded on Growth Potentialschaeffersresearch.com - April 10 at 10:47 AMGoodRx (NASDAQ:GDRX) Upgraded to "Overweight" by KeyCorpmarketbeat.com - April 10 at 8:17 AMELV vs. GDRX: Which Stock Is the Better Value Option?zacks.com - April 9 at 12:41 PMVanguard Group Inc. Buys 177,961 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)marketbeat.com - April 9 at 4:08 AM‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocksmsn.com - April 4 at 6:40 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Biomea Fusion (BMEA) and GoodRx Holdings (GDRX)markets.businessinsider.com - April 2 at 3:28 PMGoodRx Adds Publix to GoodRx Gold Networkbusinesswire.com - April 2 at 9:00 AMThis GoodRx Holdings Insider Increased Their Holding In The Last Yearfinance.yahoo.com - March 29 at 12:34 PMGoodRx (NASDAQ:GDRX) Trading Up 4.8%marketbeat.com - March 26 at 12:38 PMWells Fargo upgrades GoodRx, stock jumps 10%msn.com - March 25 at 6:54 PMTelemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst Saysmarkets.businessinsider.com - March 25 at 6:54 PMWhy GoodRx Surged Todayfool.com - March 25 at 4:24 PMWells Fargo & Company Upgrades GoodRx (NASDAQ:GDRX) to Overweightmarketbeat.com - March 25 at 7:29 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?April 22, 2024 6:05 AMView Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?All Headlines Company DescriptionsGoodRxNASDAQ:GDRXGoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
